BioGend Therapeutics Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 07, 2023 at 01:13 am IST
Share
BioGend Therapeutics Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was TWD 21.06 million compared to TWD 9.57 million a year ago. Net loss was TWD 42.37 million compared to TWD 52.04 million a year ago. Basic loss per share from continuing operations was TWD 0.36 compared to TWD 0.5 a year ago. Diluted loss per share from continuing operations was TWD 0.36 compared to TWD 0.5 a year ago.
For the nine months, sales was TWD 70.34 million compared to TWD 20.45 million a year ago. Net loss was TWD 123.62 million compared to TWD 131.14 million a year ago. Basic loss per share from continuing operations was TWD 1.04 compared to TWD 1.27 a year ago. Diluted loss per share from continuing operations was TWD 1.04 compared to TWD 1.27 a year ago.
BIOGEND THERAPEUTICS CO., LTD. is a medical equipment company mainly engaged in the development of biological aggregate. The Company is mainly engaged in the development and research of high-grade bone filling materials and knee cartilage repair related medical equipment. The Company's main products are BiG-001 which used for long bone biological aggregate, BiG-006 that used for lumbar interbody fusion biological bone, as well as BiG-009.